Review: The application of dendritic cell-derived exosomes in tumour immunotherapy

Research output: Contribution to journalReview articleResearchpeer-review

26 Citations (Scopus)

Abstract

Cancer arises from the aberrant proliferation of a single transformed cell. This population acquires the ability to metastasise. An effective way to remove cancer cells from the body is to activate tumour-specific cytotoxic T cells (CTL). Activation of naive T cells depends on the unique antigen presenting capacity of DC. Activated tumour antigen-specific CTL can destroy cancer cells without harm to normal tissue. Their ability to stimulate antigen specific T cell responses makes DC attractive candidates to potentiate anti-rumour immunity. Several studies have demonstrated the efficacy of DC based anti-tumour immunotherapy and the goal now is to optimise immune responses induced by DC, so that effective strategies in treating cancer may be realised. One way to do this is to identify DC characteristics which make them more effective in T cell stimulation. Another is to use exosomes, the antigen presenting vesicles secreted by DC, in order to induce potent anti-tumour immune responses. The non-cellular nature of exosomes offers several advantages for use in tumor immunotherapy.

Original languageEnglish
Pages (from-to)185-194
Number of pages10
JournalCancer Biotherapy and Radiopharmaceuticals
Volume15
Issue number2
DOIs
Publication statusPublished - Apr 2000
Externally publishedYes

Cite this

@article{6f53adf904fc4bceaf07e61d359b2980,
title = "Review: The application of dendritic cell-derived exosomes in tumour immunotherapy",
abstract = "Cancer arises from the aberrant proliferation of a single transformed cell. This population acquires the ability to metastasise. An effective way to remove cancer cells from the body is to activate tumour-specific cytotoxic T cells (CTL). Activation of naive T cells depends on the unique antigen presenting capacity of DC. Activated tumour antigen-specific CTL can destroy cancer cells without harm to normal tissue. Their ability to stimulate antigen specific T cell responses makes DC attractive candidates to potentiate anti-rumour immunity. Several studies have demonstrated the efficacy of DC based anti-tumour immunotherapy and the goal now is to optimise immune responses induced by DC, so that effective strategies in treating cancer may be realised. One way to do this is to identify DC characteristics which make them more effective in T cell stimulation. Another is to use exosomes, the antigen presenting vesicles secreted by DC, in order to induce potent anti-tumour immune responses. The non-cellular nature of exosomes offers several advantages for use in tumor immunotherapy.",
author = "B Quah and O'Neill, {Helen C}",
year = "2000",
month = "4",
doi = "10.1089/cbr.2000.15.185",
language = "English",
volume = "15",
pages = "185--194",
journal = "Antibody, Immunoconjugates, and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "MARY ANN LIEBERT INC PUBL",
number = "2",

}

Review: The application of dendritic cell-derived exosomes in tumour immunotherapy. / Quah, B; O'Neill, Helen C.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 15, No. 2, 04.2000, p. 185-194.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Review: The application of dendritic cell-derived exosomes in tumour immunotherapy

AU - Quah, B

AU - O'Neill, Helen C

PY - 2000/4

Y1 - 2000/4

N2 - Cancer arises from the aberrant proliferation of a single transformed cell. This population acquires the ability to metastasise. An effective way to remove cancer cells from the body is to activate tumour-specific cytotoxic T cells (CTL). Activation of naive T cells depends on the unique antigen presenting capacity of DC. Activated tumour antigen-specific CTL can destroy cancer cells without harm to normal tissue. Their ability to stimulate antigen specific T cell responses makes DC attractive candidates to potentiate anti-rumour immunity. Several studies have demonstrated the efficacy of DC based anti-tumour immunotherapy and the goal now is to optimise immune responses induced by DC, so that effective strategies in treating cancer may be realised. One way to do this is to identify DC characteristics which make them more effective in T cell stimulation. Another is to use exosomes, the antigen presenting vesicles secreted by DC, in order to induce potent anti-tumour immune responses. The non-cellular nature of exosomes offers several advantages for use in tumor immunotherapy.

AB - Cancer arises from the aberrant proliferation of a single transformed cell. This population acquires the ability to metastasise. An effective way to remove cancer cells from the body is to activate tumour-specific cytotoxic T cells (CTL). Activation of naive T cells depends on the unique antigen presenting capacity of DC. Activated tumour antigen-specific CTL can destroy cancer cells without harm to normal tissue. Their ability to stimulate antigen specific T cell responses makes DC attractive candidates to potentiate anti-rumour immunity. Several studies have demonstrated the efficacy of DC based anti-tumour immunotherapy and the goal now is to optimise immune responses induced by DC, so that effective strategies in treating cancer may be realised. One way to do this is to identify DC characteristics which make them more effective in T cell stimulation. Another is to use exosomes, the antigen presenting vesicles secreted by DC, in order to induce potent anti-tumour immune responses. The non-cellular nature of exosomes offers several advantages for use in tumor immunotherapy.

U2 - 10.1089/cbr.2000.15.185

DO - 10.1089/cbr.2000.15.185

M3 - Review article

VL - 15

SP - 185

EP - 194

JO - Antibody, Immunoconjugates, and Radiopharmaceuticals

JF - Antibody, Immunoconjugates, and Radiopharmaceuticals

SN - 1084-9785

IS - 2

ER -